BAriaTric Surgery After Breast Cancer Treatment (BATS)
Primary Purpose
Early-stage Breast Cancer, Obesity
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Bariatric Surgery with Sleeve Gastrectomy
Lifestyle Intervention
Sponsored by

About this trial
This is an interventional other trial for Early-stage Breast Cancer
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of breast cancer in the previous 10 years and currently disease free.
- Completion of breast cancer treatment (radiation, chemotherapy) at least > 6 months prior to enrollment
- Body mass index (BMI) of ≥ 35 kg/m2, but < 50 kg/m2.
- 18 through 67 years of age at enrollment
- Deemed healthy enough to undergo bariatric surgery, if assigned intervention, as determined by a surgeon and documented in the medical record.
- Must have insurance coverage with no exclusion for obesity related treatment or management of obesity related surgical complications - in general insurance coverage is available for persons with a BMI ≥ 35 kg/m2.
- Anticipated ability to abide by study requirements demonstrated in part by, but not limited to, successful completion of run-in assessments.
- Willingness to accept randomization into either interventional group.
- Provides voluntary written consent prior to performance of any research related activities.
Exclusion Criteria:
- Cardiovascular event (myocardial infarction, acute coronary syndrome, coronary artery angioplasty or bypass, stroke) in the past six months.
- Current evidence of congestive heart failure, angina pectoris, or symptomatic peripheral vascular disease.
- Cardiac stress test indicating that surgery or lifestyle would not be safe.
- 12-lead EKG indicating that surgery would not be safe.
- Significant anemia (hemoglobin 1.0 g/dL or more below normal range) or history of coagulopathy.
- History of stomach surgery, bile duct surgery, pancreatic surgery, splenectomy, or colon resection.
- Gastric or duodenal ulcer in the past six months.
- History of intra-abdominal sepsis except for uncomplicated appendicitis or diverticulitis more than six months prior to enrollment.
- Self-reported HIV-positive status, active tuberculosis, active malaria, chronic hepatitis B or C, cirrhosis, or inflammatory bowel disease.
- Currently pregnant or nursing, or planning to become pregnant in the next 15 months.
- History of alcohol, drug, or opioid dependency (excluding nicotine) in the past five years.
- Active psychosocial or psychiatric problem that is likely to interfere with adherence to the protocol.
- Deemed not an acceptable candidate by a trained psychologist.
- Current participation in a conflicting research protocol.
- Presence of any chronic or debilitating disease that would make adherence to the protocol difficult.
- Gastroesophageal reflux disease requiring medications. History of endoscopy demonstrating esophagitis or Barrett's changes in the esophagus.
- Any history of dysphagia.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Sleeve Gastrectomy & Lifestyle Intervention
Lifestyle Intervention
Arm Description
Outcomes
Primary Outcome Measures
Feasibility of Weight Loss Intervention
Feasibility for women who were diagnosed with early stage breast cancer in the previous 10 years and have a body mass index (BMI) of ≥ 35 kg/m2 but < 50 kg/m2.
Acceptability of Weight Loss Intervention
Acceptability of women who were diagnosed with early stage breast cancer in the previous 10 years and have a body mass index (BMI) of ≥ 35 kg/m2 but < 50 kg/m2.
Secondary Outcome Measures
Weight Loss
Percent body mass weight loss
Breast Cancer Recurrence
Incidence of breast cancer recurrence
Cancer Related Mortality
Incidence of cancer related mortality
Overall Mortality
Incidence of overall mortality
Full Information
NCT ID
NCT03946423
First Posted
May 8, 2019
Last Updated
May 25, 2023
Sponsor
Masonic Cancer Center, University of Minnesota
1. Study Identification
Unique Protocol Identification Number
NCT03946423
Brief Title
BAriaTric Surgery After Breast Cancer Treatment (BATS)
Official Title
BAriaTric Surgery After Breast Cancer Treatment (BATS) - A Randomized Trial of Sleeve Gastrectomy Versus Lifestyle Intervention in Women Diagnosed With Early Stage Breast and With a BMI of ≥ 35
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 2023 (Anticipated)
Primary Completion Date
February 2025 (Anticipated)
Study Completion Date
February 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Masonic Cancer Center, University of Minnesota
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
This is a feasibility study to gain an understanding of the willingness of women with a history of early stage breast cancer and current obesity to enroll in a weight-loss study, accept an assigned intervention (bariatric surgery with lifestyle intervention or lifestyle intervention alone), and comply with the study plan for 1 year. If there is successful enrollment in this study, the plan is to use what is learned in this study to design a larger, longer-term clinical trial to look at the effect of weight loss and incidence of cancer recurrence.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Early-stage Breast Cancer, Obesity
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Sleeve Gastrectomy & Lifestyle Intervention
Arm Type
Experimental
Arm Title
Lifestyle Intervention
Arm Type
Active Comparator
Intervention Type
Procedure
Intervention Name(s)
Bariatric Surgery with Sleeve Gastrectomy
Intervention Description
Standard of care bariatric surgery with sleeve gastrectomy
Intervention Type
Behavioral
Intervention Name(s)
Lifestyle Intervention
Intervention Description
All participants receive lifestyle intervention. The lifestyle intervention program is modeled closely after that used in the Diabetes Primary Prevention Trial and the LookAHEAD diabetes treatment studies. Intervention includes counseling sessions weekly for the first six months, twice a month during months 7-9, and monthly during months 10-12, and energy intake and exercise goal monitoring and guidance.
Primary Outcome Measure Information:
Title
Feasibility of Weight Loss Intervention
Description
Feasibility for women who were diagnosed with early stage breast cancer in the previous 10 years and have a body mass index (BMI) of ≥ 35 kg/m2 but < 50 kg/m2.
Time Frame
1 Year
Title
Acceptability of Weight Loss Intervention
Description
Acceptability of women who were diagnosed with early stage breast cancer in the previous 10 years and have a body mass index (BMI) of ≥ 35 kg/m2 but < 50 kg/m2.
Time Frame
1 Year
Secondary Outcome Measure Information:
Title
Weight Loss
Description
Percent body mass weight loss
Time Frame
1 Year
Title
Breast Cancer Recurrence
Description
Incidence of breast cancer recurrence
Time Frame
1 Year
Title
Cancer Related Mortality
Description
Incidence of cancer related mortality
Time Frame
1 Year
Title
Overall Mortality
Description
Incidence of overall mortality
Time Frame
1 Year
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
67 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of breast cancer in the previous 10 years and currently disease free.
Completion of breast cancer treatment (radiation, chemotherapy) at least > 6 months prior to enrollment
Body mass index (BMI) of ≥ 35 kg/m2, but < 50 kg/m2.
18 through 67 years of age at enrollment
Deemed healthy enough to undergo bariatric surgery, if assigned intervention, as determined by a surgeon and documented in the medical record.
Must have insurance coverage with no exclusion for obesity related treatment or management of obesity related surgical complications - in general insurance coverage is available for persons with a BMI ≥ 35 kg/m2.
Anticipated ability to abide by study requirements demonstrated in part by, but not limited to, successful completion of run-in assessments.
Willingness to accept randomization into either interventional group.
Provides voluntary written consent prior to performance of any research related activities.
Exclusion Criteria:
Cardiovascular event (myocardial infarction, acute coronary syndrome, coronary artery angioplasty or bypass, stroke) in the past six months.
Current evidence of congestive heart failure, angina pectoris, or symptomatic peripheral vascular disease.
Cardiac stress test indicating that surgery or lifestyle would not be safe.
12-lead EKG indicating that surgery would not be safe.
Significant anemia (hemoglobin 1.0 g/dL or more below normal range) or history of coagulopathy.
History of stomach surgery, bile duct surgery, pancreatic surgery, splenectomy, or colon resection.
Gastric or duodenal ulcer in the past six months.
History of intra-abdominal sepsis except for uncomplicated appendicitis or diverticulitis more than six months prior to enrollment.
Self-reported HIV-positive status, active tuberculosis, active malaria, chronic hepatitis B or C, cirrhosis, or inflammatory bowel disease.
Currently pregnant or nursing, or planning to become pregnant in the next 15 months.
History of alcohol, drug, or opioid dependency (excluding nicotine) in the past five years.
Active psychosocial or psychiatric problem that is likely to interfere with adherence to the protocol.
Deemed not an acceptable candidate by a trained psychologist.
Current participation in a conflicting research protocol.
Presence of any chronic or debilitating disease that would make adherence to the protocol difficult.
Gastroesophageal reflux disease requiring medications. History of endoscopy demonstrating esophagitis or Barrett's changes in the esophagus.
Any history of dysphagia.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sara Eischen
Phone
612-624-0902
Email
bengt008@umn.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anne Blaes, MD
Organizational Affiliation
University of Minnesota, Division of Hematology, Oncology and Transplantation
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
BAriaTric Surgery After Breast Cancer Treatment (BATS)
We'll reach out to this number within 24 hrs